{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:06:06Z","timestamp":1762956366333,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.arbres.2020.03.021","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T17:48:38Z","timestamp":1589996918000},"page":"514-521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Actualizaci\u00f3n de la normativa SEPAR \u00abDiagn\u00f3stico y tratamiento de la tuberculosis con resistencia a f\u00e1rmacos\u00bb"],"prefix":"10.1016","volume":"56","author":[{"given":"Jos\u00e9 A.","family":"Caminero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Mar\u00eda","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan A.","family":"Cayl\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Garc\u00eda-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ruiz-Manzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2020.03.021_bib0220","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.arbres.2017.02.006","article-title":"Diagn\u00f3stico y tratamiento de la tuberculosis con resistencia a f\u00e1rmacos","volume":"53","author":"Caminero","year":"2017","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2020.03.021_bib0225","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-2600(18)30078-X","article-title":"Comparison of different treatments for isoniazid-resistant tuberculosis: An individual patient data meta-analysis","volume":"6","author":"Fregonese","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2020.03.021_bib0230","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"The Collaborative Group for the Meta-analysis of Individual Patient Data in MDR-TB Treatment 2017 Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual data and meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2020.03.021_bib0235","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2020.03.021_bib0240","unstructured":"World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis. Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. World Health Organization Document 2018. Licence: CC BY-NC-SA 3.0 IGO. WHO\/CDS\/TB\/2018.7: 1-31 [consultado 21 Ene 2020]. Disponible en: https:\/\/www.who.int\/tb\/publications\/2018\/WHO_guidelines_isoniazid_resistant_TB\/en\/"},{"key":"10.1016\/j.arbres.2020.03.021_bib0245","unstructured":"WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO [consultado 21 Ene 2020]. Disponible en: https:\/\/www.who.int\/tb\/publications\/2019\/consolidated-guidelines-drug-resistant-TB-treatment\/en\/"},{"key":"10.1016\/j.arbres.2020.03.021_bib0250","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.arbres.2020.03.021_bib0255","unstructured":"World Health Organization. Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children: Rapid communication. Policy update. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO [consultado 21 Ene 2020]. Disponible en: https:\/\/apps.who.int\/iris\/handle\/10665\/330395"},{"key":"10.1016\/j.arbres.2020.03.021_bib0260","unstructured":"Rapid communication: Key changes to treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2019 (WHO\/CDS\/TB\/2019.26). Licence: CC BY-NC-SA 3.0 IGO [consultado 21 Ene 2020]. Disponible en: https:\/\/www.who.int\/tb\/publications\/2019\/rapid_communications_MDR\/en\/"},{"year":"2020","series-title":"Frequently asked questions on the WHO rapid communication 2019: Key changes to the treatment of drug-resistant TB Version: 1. 1","key":"10.1016\/j.arbres.2020.03.021_bib0265"},{"key":"10.1016\/j.arbres.2020.03.021_bib0270","unstructured":"Global Laboratory Initiative. Planning for country transition to Xpert MTB\/RIF Ultra Cartridges. Global Laboratory Initiative, 2017 [consultado 21 Ene 2020]. Disponible en: http:\/\/www.stoptb.org\/wg\/gli\/assets\/documents\/GLI_ultra.pdf"},{"key":"10.1016\/j.arbres.2020.03.021_bib0275","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1473-3099(17)30691-6","article-title":"Xpert MTB\/RIF ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: A prospective multicentre diagnostic accuracy study","volume":"18","author":"Dorman","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arbres.2020.03.021_bib0280","article-title":"Multicenter study of the accuracy of the BD MAX\u2122 MDR-TB assay for detection of Mycobacterium tuberculosis complex and mutations associated with resistance to rifampin and isoniazid","author":"Shah","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arbres.2020.03.021_bib0285","doi-asserted-by":"crossref","first-page":"e0218890","DOI":"10.1371\/journal.pone.0218890","article-title":"Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector","volume":"14","author":"Lee","year":"2019","journal-title":"PLos One"},{"key":"10.1016\/j.arbres.2020.03.021_bib0290","doi-asserted-by":"crossref","first-page":"1701354","DOI":"10.1183\/13993003.01354-2017","article-title":"A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis","volume":"50","author":"Miotto","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2020.03.021_bib0295","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa1800474","article-title":"Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2020.03.021_bib0300","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.arbres.2019.01.002","article-title":"The future of TB resistance diagnosis: The essentials on whole genome sequencing and rapid testing methods","volume":"55","author":"Moreno-Molina","year":"2019","journal-title":"Arch Bronconeumol"},{"issue":"Suppl. 2","key":"10.1016\/j.arbres.2020.03.021_bib0305","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications","volume":"3","author":"Fox","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.arbres.2020.03.021_bib0310","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(19)30696-8","article-title":"Multidrug-resistant tuberculosis","volume":"394","author":"Caminero","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.arbres.2020.03.021_bib0315","doi-asserted-by":"crossref","first-page":"1901272","DOI":"10.1183\/13993003.01272-2019","article-title":"The future of drug-resistant tuberculosis treatment: Learning from the past and the 2019 World Health Organization consolidated guidelines","volume":"54","author":"Caminero","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2020.03.021_bib0320","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1183\/13993003.00432-2015","article-title":"Classification of anti-TB drugs: A new potential proposal based on the most recent evidence","volume":"46","author":"Caminero","year":"2015","journal-title":"Eur Respir J."},{"key":"10.1016\/j.arbres.2020.03.021_bib0325","series-title":"Tuberculosis (ERS Monograph).","first-page":"152","article-title":"Treatment of drug-susceptible and drug-resistant tuberculosis","author":"Caminero","year":"2018"},{"key":"10.1016\/j.arbres.2020.03.021_bib0330","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMc1505196","article-title":"Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis","volume":"373","author":"Bloemberg","year":"2015","journal-title":"N Eng J Med"},{"key":"10.1016\/j.arbres.2020.03.021_bib0335","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMc1815121","article-title":"Bedaquiline microheteroresistance after cessation of tuberculosis treatment","volume":"380","author":"De Vos","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2020.03.021_bib0340","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(16)30407-8","article-title":"Treatment of isoniazid-resistant tuberculosis with first-line drugs: A systematic review and meta-analysis","volume":"17","author":"Gegia","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arbres.2020.03.021_bib0345","doi-asserted-by":"crossref","first-page":"1700061","DOI":"10.1183\/13993003.00061-2017","article-title":"Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: Individual patient data and aggregate data meta-analysis","volume":"50","author":"Ahmad Khan","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2020.03.021_bib0350","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","author":"Nunn","year":"2019","journal-title":"N Eng J Med"},{"key":"10.1016\/j.arbres.2020.03.021_bib0355","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.2009.03595.x","article-title":"Levofloxacin can be used effectively as a positive control in thorough QT\/QTc studies in healthy volunteers","volume":"69","author":"Taubel","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.arbres.2020.03.021_bib0360","doi-asserted-by":"crossref","first-page":"190035","DOI":"10.1183\/16000617.0035-2019","article-title":"Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives","volume":"28","author":"Pontali","year":"2019","journal-title":"Eur Respir Rev."},{"key":"10.1016\/j.arbres.2020.03.021_bib0365","unstructured":"TB Alliance. FDA Advisory Committee votes favorably on the question of the ffectiveness and safety of pretomanid in combination with bedaquiline and linezolid for treatment of highly drug-resistant forms of tuberculosis. 2019 [consultado 7 Jun 2019]. Disponible en: https:\/\/www.tballiance.org\/news\/fda-advisory-committee-votes-favorably-question-effectiveness-and-safety-pretomanid-combination"},{"key":"10.1016\/j.arbres.2020.03.021_bib0370","unstructured":"TB Alliance. FDA approves new treatment for highly drug-resistant forms of tuberculosis [consultado 24 Ene 2020]. Disponible en: https:\/\/www.tballiance.org\/news\/fda-approves-new-treatment-highly-drug-resistant-forms-tuberculosis"},{"key":"10.1016\/j.arbres.2020.03.021_bib0375","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2020.03.021_bib0380","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ccm.2019.08.001","article-title":"New drugs for the treatment of tuberculosis","volume":"40","author":"Ignatius","year":"2019","journal-title":"Clin Chest Med."},{"key":"10.1016\/j.arbres.2020.03.021_bib0385","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(19)30692-0","article-title":"Multidrug-resistant tuberculosis. Author\u015breply","volume":"394","author":"Menzies","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.arbres.2020.03.021_bib0390","unstructured":"Management of drug-resistant tuberculosis in children: A field guide. Boston, USA: The Sentinel Project for Pediatric Drug-Resistant Tuberculosis; November 2018, Fourth edition [consultado 23 Ene 2020]. Disponible en: http:\/\/www.stoptb.org\/wg\/dots_expansion\/childhoodtb\/assets\/documents\/Updated_DRTB-Field-Guide-2019-V3.pdf"},{"key":"10.1016\/j.arbres.2020.03.021_bib0395","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2020.03.021_bib0400","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"Blanc","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2020.03.021_bib0405","unstructured":"Treatment of LTBI and TB for persons with HIV. CDC, last revision April 2016) [consultado 13 Ene 2020]. Disponible en: https:\/\/www.cdc.gov\/tb\/topic\/treatment\/tbhiv.htm"},{"key":"10.1016\/j.arbres.2020.03.021_bib0410","unstructured":"Panel de Expertos del Grupo de estudio de Sida (Gesida-SEIMC). Recomendaciones de Gesida sobre el tratamiento de la tuberculosis en adultos infectados por el virus de la inmunodeficiencia humana (actualizaci\u00f3n mayo de 2018) [consultado 13 Ene 2020]. Disponible en: http:\/\/gesida-seimc.org\/wp-content\/uploads\/2018\/06\/gesida_TB_en_VIH_Version_FINAL_5_de_junio_2018.pdf"},{"key":"10.1016\/j.arbres.2020.03.021_bib0415","article-title":"Tuberculosis-HIV co-infection: Progress and challenges after two decades of global antiretroviral treatment roll-out","author":"Letang","year":"2019","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.arbres.2020.03.021_bib0420","unstructured":"Plan para la Prevenci\u00f3n y Control de la TB en Espa\u00f1a. Madrid: Ministerio de Sanidad, Consumo y Bienestar Social; 2019 [consultado Jun 2019]. Disponible en: https:\/\/www.mscbs.gob.es\/en\/profesionales\/saludPublica\/prevPromocion\/PlanTuberculosis\/docs\/PlanTB2019.pdf"},{"key":"10.1016\/j.arbres.2020.03.021_bib0425","doi-asserted-by":"crossref","first-page":"385","DOI":"10.5588\/ijtld.14.0335","article-title":"QTc prolongation and treatment of multidrug-resistant tuberculosis","volume":"19","author":"Harausz","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.arbres.2020.03.021_bib0430","doi-asserted-by":"crossref","first-page":"996","DOI":"10.5588\/ijtld.17.0174","article-title":"Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease","volume":"21","author":"Yoon","year":"2017","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289620301010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289620301010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:38:45Z","timestamp":1759531125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289620301010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0300289620301010"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2020.03.021","relation":{},"ISSN":["0300-2896"],"issn-type":[{"type":"print","value":"0300-2896"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualizaci\u00f3n de la normativa SEPAR \u00abDiagn\u00f3stico y tratamiento de la tuberculosis con resistencia a f\u00e1rmacos\u00bb","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2020.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}